Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide orodispersible tablets in active eosinophilic esophagitis
NCT02434029Phase 3Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Nov 2015
- Primary completion
- Aug 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of EPI-EE in eosinophilic esophagitis (EoE), sponsored by Dr. Falk Pharma GmbH. Started Nov 2015; status: completed.
02
Drugs
EPI-EE
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT02434029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02434029.